yes, I had kind of written off the BT drug mostly because I don't know much about the company, but that looks interesting. The Sanofi drug is an antibody, not an ADC. The Sanofi-IMGN ADC in phase II update is an abstract, so it seems like that drug may not be competitive, which is disappointing. Not sure if that one uses the same linker and DM1. I seem to recall IMGN saying this ADC uses a non-potent, dummy molecule? I wish IMGN would spell out in detail on the web site, the molecule, linker and killing agent used for each molecule.
If you go to ASH2013 website all three papers are available to read, just click on abstracts and then put in number of abstract 284, 758 and 4395. Since you are more knowledgeable than most of us let us know what you think. Thanks.